G1 Therapeutics to Present at UBS Global Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., May 13, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present a company overview at the UBS Global Healthcare Conference. The presentation will take place on Tuesday, May 21 at 4:00 p.m. ET at the Grand Hyatt New York in New York, NY.

To access the live webcast presentation, please visit the Events & Presentations page within the Investors section of the G1 website. Replays of the webcasts will be archived on the same page for 90 days following the event.

About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. Trilaciclib and lerociclib are designed to enable more effective combination treatment strategies and improve patient outcomes across multiple oncology indications. G1T48 is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. G1 also has an active discovery program focused on cyclin-dependent kinase targets.

G1 is based in Research Triangle Park, NC. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contact:
Jeff Macdonald
Head of Investor Relations / Public Relations
919-907-1944
[email protected]

You May Also Be Interested In

• Dimensional Fund Advisors Ltd. : Form 8.3 - Consortium comprising LondonMetric Property plc and Schroder Real Estate Investment Trust Limited
• Atlantico's ioGAS Interpretation Identifies Multiple Rare Earth Anomalies as Higher-TREO Sample Locations Span 19.4 Kilometres at Novo Cruzeiro
• New American Industrial Alliance and Exiger Kick-Off Survey on Critical Minerals Scarcity